Comparing a new PET scan agent to the standard for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study compares a new PET/CT imaging agent (61Cu-NU101) with the standard one (Pylarify) to see if it's better at detecting prostate cancer that has spread to a few places. If you have oligometastatic prostate cancer, this trial might help improve how doctors find and monitor your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer (confirmed by biopsy).
- You are 18 years of age or older.
- You are able to carry out daily activities (fully active or up and about more than half the day).
- Your most recent PET/CT scan (within the last month) showed that the cancer has spread to only a few spots (1 to 5).
- You are not allergic to PSMA-targeted imaging agents.
- You do not have any other active cancer besides prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that looks for a protein called uPAR on prostate cancer cells. It might help doctors see your cancer more clearly without needing surgery or treatment first.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This trial tests a new imaging drug that may help your doctor see the exact location of prostate cancer using a PET scan. The imaging is done before surgery to remove the prostate or, if you have recurrence, to find where the cancer has returned.
This study looks at how well two different PSMA PET scans work for men with advanced prostate cancer. The scans help doctors see where the cancer is, which can guide treatment decisions and help you and your doctor plan next steps.
This study tests a new imaging agent (INR101) used with a PET/CT scan to help see prostate cancer before surgery. The scan may help doctors plan your prostate removal surgery more accurately.
This trial provides access to a new type of PET/CT scan called 18F-PSMA-1007, which uses a radioactive tracer to find prostate cancer cells that may have spread in the body. The scan may help your doctor plan your treatment more accurately.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.